Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.57 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.53 |
| ▸ | CBX7 | O95931 | 1/20 | 0.52 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967991 | 0.89 | ADAMTS5 (0.52) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL4590472 | 0.89 | CBX7 (0.52) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL15619568 | 0.89 | BRD4 (0.62) | BRD4HTR6MEN1KMT2APOLB | |
| SCHEMBL2499643 | 0.86 | CDYL (0.60) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL27529257 | 0.86 | IDO1 (0.49) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL2496723 | 0.85 | BRD4 (0.61) | BRD4ADAMTS5KMT2APOLBCASP6 | |
| SCHEMBL15619861 | 0.84 | BRD4 (0.57) | BRD4ADAMTS5HTR6KMT2APOLB | |
| SCHEMBL2889479 | 0.83 | CBX7 (0.52) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL2497429 | 0.83 | CBX7 (0.52) | BRD4ADAMTS5CBX7CDYLIDO1 | |
| SCHEMBL4588841 | 0.82 | ADAMTS5 (0.54) | BRD4ADAMTS5CBX7CDYLIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| EP-1296976-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098295-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293319-A1 | Oxindole derivatives | CCNI, OGFR, MKI67 | BRD4 1561/4885ADAMTS5 2290/4885CBX7 1783/4885 |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | BRD4 2445/4885ADAMTS5 1714/4885CBX7 4049/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | BRD4 2256/4885ADAMTS5 1357/4885CBX7 3930/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | BRD4 822/4885ADAMTS5 1111/4885CBX7 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.